Cytokinetics Still A Buy After Phase 2 SMA Data
March 23, 2017 at 08:46 AM EDT
Data presented by Cytokinetics, Inc. (NASDAQ: CYTK) showed CK-107 has the ability to positively impact two different animal models of ...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.